XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | 1.23 | 2.05 | +66.67% | $237.5M | ✅ Beat | +3.33% | -4.70% | -2.11% |
| 2026-02-27 | Q4 2025 | 1.83 | 2.33 | +27.32% | $247.1M | ✅ Beat | +2.13% | +0.19% | -0.26% |
| 2025-11-07 |
| Q3 2025 |
| 1.61 |
| 2.04 |
| +26.71% |
| $227.8M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-08 | Q2 2025 | 1.26 | 1.80 | +42.86% | $211.4M | ✅ Beat | +5.77% | +7.35% | +16.84% |
| 2025-05-09 | Q1 2025 | -0.06 | 1.70 | +2933.33% | $197.1M | ✅ Beat | — | — | — |
| 2025-02-28 | Q4 2024 | 0.29 | 1.63 | +462.07% | $190.6M | ✅ Beat | — | — | — |
| 2024-11-08 | Q3 2024 | 1.09 | 1.34 | +22.94% | $148.3M | ✅ Beat | — | — | — |
| 2024-08-06 | Q2 2024 | 0.94 | 1.02 | +8.51% | $138.0M | ✅ Beat | — | — | — |
Showing last 8 quarters.